Results 181 to 190 of about 1,261,128 (384)

Changing perspectives on liver transplantation in 1988. [PDF]

, 1988
After liver transplantation for cancer, there is a high incidence of disease recurrence within 18 to 36 months for most tumors, although there are a small number of long-term survivors.
Gordon, RD, Starzl, TE
core  

Portal Hypertension Secondary to an Hepato-Portal Arteriovenous Fistula

, 1961
John Foster, P Sandblom
openalex   +2 more sources

Effects of Shunt Position on the Prognosis of Transjugular Intrahepatic Portosystemic Shunt in Patients With Cirrhotic Esophagogastric Variceal Bleeding

Portal Hypertension &Cirrhosis, EarlyView.
The challenge of transjugular intrahepatic portosystemic shunt (TIPS) remains the puncture of the portal vein. Establishing an optimal shunt position in the left branch of the portal vein would be a better option for reducing the risk of postoperative hepatic encephalopathy and stent dysfunction.
Yi‐Han Yang, Ze Wang, Chen‐Chen Lu, Wan‐Ci Li, Shuai Zhang, Jian Shen, Xiao‐Li Zhu   +6 more
wiley   +1 more source

Portal Hypertension Secondary to Pancreatic Disease *

, 1960
William V. McDicrmott
openalex   +2 more sources

Hepatic blood flow in patients with alcoholic liver cirrhosis [PDF]

, 2015
This research is devoted to studying of hepatic blood flow in patients with alcoholic liver cirrhosis (ALC). The presence of endothelial dysfunction (ED) in cirrhotic patients directly correlates with the diameter of portal vein (r = 0,673) and with the
Muslimov, K.I., Slyvka, Nataliia Oleksyivna   +1 more
core  

Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Given the high prevalence of the population who have metabolic dysfunction‐associated steatohepatitis (MASH), interest is growing in MASH‐targeted treatments. However, currently, there has been only one regulatory approved drug for MASH (Rezdiffra).
Quyen Thi Tran, Tham Thi Bui, Lien Thi Ngo, Bo Ram Yang, In‐Hwan Baek, Van Hung Nguyen, Kyung Ae Lee, Hwi‐yeol Yun, Jung‐woo Chae, Soyoung Lee, Jae Hyun Kim, Woojin Jung   +11 more
wiley   +1 more source

A Computer Based Index for the Prediction of Operative Survival in Patients with Cirrhosis and Portal Hypertension

, 1969
John H. Siegel, James B. Williams
openalex   +2 more sources

A New Classification System for Fatty Liver—What Sonographers Should Know

Sonography, EarlyView.
ABSTRACT Hepatic steatosis or fatty liver disease is a rapidly emerging health issue and is closely linked to an increase in cardiometabolic conditions such as obesity and type 2 diabetes. The nomenclature surrounding fatty liver has recently undergone multiple reviews to better reflect its underlying causes.
Elspeth L. Keys, Katie L. McMahon, Elizabeth Powell, Heather Allen, Christopher Edwards   +4 more
wiley   +1 more source

Diagnosis and Monitoring Pathways Using Non‐Invasive Tests in Patients With Alpha‐1 Antitrypsin Deficiency‐Associated Liver Disease: Results From an Expert Delphi Panel

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims The severe alpha‐1 antitrypsin deficiency (AATD) genotype Pi*ZZ increases the risk of liver disease (AATD‐LD) and lung disease. While non‐invasive tests (NITs) are widely used for fibrosis stage and monitoring of all liver diseases, the consensus for use in AATD‐LD is limited.
Virginia C. Clark, Mark A. Price, Jon Russo, Rohit Loomba, Alice M. Turner, Pavel Strnad   +5 more
wiley   +1 more source

MEASUREMENT OF BLOOD FLOW THROUGH PORTOPULMONARY ANASTOMOSIS IN PORTAL HYPERTENSION

, 1965
Teizo Tazawa
openalex   +2 more sources